Beigene Ltd Ads (BGNE)

$345.00 9.04 (2.69%)

18:43 EST BGNE Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 18.55B

PE Ratio -115.38

EPS -2.99

Volume (Avg. Vol.) 502,400

Day's Range 331.46 - 345.98

52-Week Range 118.55 - 345.98

Dividend & Yield N/A (N/A)

BGNE Stock Predictions, Articles, and Beigene Ltd Ads News

From the Web

Week In Review: BeiGene Signs $2.2 Billion Deal With Novartis For PD-1

From Talk Markets Jan 16, 2021

Beijing's BeiGene out-licensed ex-China rights for tislelizumab, its anti-PD-1 antibody, to Novartis in a $2.2 billion agreement. The deal includes a $650 million upfront payment to BeiGene, plus up to $1.3 billion in regulatory milestones.

Three Governments In Trouble

From Talk Markets Jan 15, 2021

Three countries are now in an interregnum: the USA, Italy, and The Netherlands.

Stock Market Rally Pauses Amid Trump Impeachment, Biden Stimulus Plan; GM, Nio, Intel, Taiwan Semiconductor, JPMorgan In Focus

From Investor's Business Daily Jan 15, 2021

The stock market rally paused this week amid a new Trump impeachment and a Biden stimulus plan. Major indexes fell, but small caps and many leaders rose.

BeiGene (BGNE) Up on Label Expansion of Tislelizumab in China

From Zacks Investment Research Jan 15, 2021

BeiGene (BGNE) gains following the approval of tislelizumab for the lucrative indication of advanced squamous non-small cell lung cancer in China.

The Daily Biotech Pulse: DBV's Positive FDA Feedback, Pfizer's Cancer Drug Gets Label Expansion, Applied DNA COVID Testing Volume Surges

From Benzinga Jan 15, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 14) 10X Genomics Inc (NASDAQ:...

Bimbo 3

From Talk Markets Jan 14, 2021

The US stock indexes today are all in the black.

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy